CN114685374A - 一种合成奥拉帕尼的新工艺 - Google Patents
一种合成奥拉帕尼的新工艺 Download PDFInfo
- Publication number
- CN114685374A CN114685374A CN202011584050.0A CN202011584050A CN114685374A CN 114685374 A CN114685374 A CN 114685374A CN 202011584050 A CN202011584050 A CN 202011584050A CN 114685374 A CN114685374 A CN 114685374A
- Authority
- CN
- China
- Prior art keywords
- chloride
- dichloromethane
- mixed solution
- olaparib
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 229960000572 olaparib Drugs 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 20
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 105
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 69
- 239000011259 mixed solution Substances 0.000 claims abstract description 34
- 238000003756 stirring Methods 0.000 claims abstract description 34
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims abstract description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
- 150000001263 acyl chlorides Chemical class 0.000 claims description 3
- 229910006124 SOCl2 Inorganic materials 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- NWDTXGSUPILYAV-UHFFFAOYSA-N cyclopropane;formic acid Chemical compound C1CC1.OC=O NWDTXGSUPILYAV-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011584050.0A CN114685374B (zh) | 2020-12-28 | 2020-12-28 | 一种合成奥拉帕尼的新工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011584050.0A CN114685374B (zh) | 2020-12-28 | 2020-12-28 | 一种合成奥拉帕尼的新工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114685374A true CN114685374A (zh) | 2022-07-01 |
CN114685374B CN114685374B (zh) | 2024-04-12 |
Family
ID=82130108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011584050.0A Active CN114685374B (zh) | 2020-12-28 | 2020-12-28 | 一种合成奥拉帕尼的新工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114685374B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101810612A (zh) * | 2009-12-22 | 2010-08-25 | 北京欧凯纳斯科技有限公司 | 荜拔酰胺类化合物抗血小板聚集的用途 |
WO2011151436A2 (en) * | 2010-06-04 | 2011-12-08 | Euroscreen S.A. | Novel compounds, method for use them and pharmaceutical composition containing them |
CN102372698A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
CN105820126A (zh) * | 2016-05-12 | 2016-08-03 | 山东罗欣药业集团恒欣药业有限公司 | 一种奥拉帕尼的制备方法 |
CN106928149A (zh) * | 2015-12-30 | 2017-07-07 | 石药集团中奇制药技术(石家庄)有限公司 | 一种奥拉帕尼的制备方法 |
CN108129397A (zh) * | 2018-02-11 | 2018-06-08 | 北京耀诚惠仁科技有限公司 | 一种奥拉帕尼的合成方法 |
CN110790710A (zh) * | 2019-11-07 | 2020-02-14 | 东南大学 | 奥拉帕尼的合成方法 |
CN112047890A (zh) * | 2020-10-20 | 2020-12-08 | 连云港杰瑞药业有限公司 | 一种奥拉帕尼制备方法 |
-
2020
- 2020-12-28 CN CN202011584050.0A patent/CN114685374B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101810612A (zh) * | 2009-12-22 | 2010-08-25 | 北京欧凯纳斯科技有限公司 | 荜拔酰胺类化合物抗血小板聚集的用途 |
WO2011151436A2 (en) * | 2010-06-04 | 2011-12-08 | Euroscreen S.A. | Novel compounds, method for use them and pharmaceutical composition containing them |
CN102372698A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
CN106928149A (zh) * | 2015-12-30 | 2017-07-07 | 石药集团中奇制药技术(石家庄)有限公司 | 一种奥拉帕尼的制备方法 |
CN105820126A (zh) * | 2016-05-12 | 2016-08-03 | 山东罗欣药业集团恒欣药业有限公司 | 一种奥拉帕尼的制备方法 |
CN108129397A (zh) * | 2018-02-11 | 2018-06-08 | 北京耀诚惠仁科技有限公司 | 一种奥拉帕尼的合成方法 |
CN110790710A (zh) * | 2019-11-07 | 2020-02-14 | 东南大学 | 奥拉帕尼的合成方法 |
CN112047890A (zh) * | 2020-10-20 | 2020-12-08 | 连云港杰瑞药业有限公司 | 一种奥拉帕尼制备方法 |
Non-Patent Citations (1)
Title |
---|
张克勋等: ""环丙烷甲酰氯的合成", 化工时刊, vol. 17, no. 7, pages 36 * |
Also Published As
Publication number | Publication date |
---|---|
CN114685374B (zh) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114195671A (zh) | 一种不对称丙二酰苯胺类化合物及其合成方法 | |
CN113416150A (zh) | 一种洛铂中间体的新合成方法 | |
CN114685374A (zh) | 一种合成奥拉帕尼的新工艺 | |
Niu et al. | The Pd-catalyzed synthesis of difluoroethyl and difluorovinyl compounds with a chlorodifluoroethyl iodonium salt (CDFI) | |
Zhan et al. | Copper/silver cocatalyzed regioselective C5–H functionalization of 8-aminoquinoline amides with 1, 3-dicarbonyl compounds | |
CN111995614B (zh) | 硫代羟基乙酸酐的制备方法 | |
CN111072660A (zh) | 一种瑞来巴坦的简便制备方法 | |
CN113105505A (zh) | 丙酚替诺福韦降解杂质的制备方法 | |
CN114539252A (zh) | 一种2,3-二氢喹啉-4-酮生物活性骨架及其合成方法和应用 | |
CN110804022B (zh) | 一种右丙亚胺的制备方法 | |
TW202210462A (zh) | (s)-2-胺基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其鹽的製備方法 | |
CN103570803B (zh) | 一种阿加曲班中间体的制备方法 | |
CN112624957A (zh) | 一种3-烷基异吲哚啉酮类衍生物的合成方法 | |
CN114907261B (zh) | 2-苯氨基喹啉衍生物及其制备方法和应用 | |
CN100436423C (zh) | 一种n-氯甲酰基亚胺基二苄的化学合成方法 | |
CN101113138A (zh) | 二茂铁亚胺环钯配合物催化下芳基腈类衍生物的合成方法 | |
CN115232022B (zh) | 一种对乙酰氨基酚二聚体衍生物的制备方法 | |
CN113292624B (zh) | 一种乙酸阿比特龙酯杂质的合成方法 | |
CN113527141B (zh) | 一种螺[2,5]辛烷衍生物的合成方法 | |
CN114805326A (zh) | 瑞卢戈利杂质的制备工艺 | |
CN107602602A (zh) | 一种3‑氰基吡啶‑5‑硼酸频哪醇酯的合成方法 | |
CN113087655B (zh) | 一种左布比卡因中间体化合物 | |
CN105777766B (zh) | Delta‑7溴甲纳曲酮的制备方法 | |
CN117209537A (zh) | 瑞卢戈利中间体杂质、瑞卢戈利杂质及其制备方法 | |
CN105399683A (zh) | 苯并咪唑衍生物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: No. 69 Yinhai Second Road, Binhai New Area, Lijin County, Dongying City, Shandong Province, 257453 Applicant after: Shandong Daohe Pharmaceutical Co.,Ltd. Applicant after: Daohe (Weifang) Pharmaceutical Technology Co.,Ltd. Address before: 257000 Binhai fine chemical industry park, dongyinggang Economic Development Zone, Dongying City, Shandong Province Applicant before: SHANDONG DOYE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Country or region before: China Applicant before: Shandong Daozhen Pharmaceutical Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |